PMID- 35261049
OWN - NLM
STAT- MEDLINE
DCOM- 20220803
LR  - 20221004
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 97
IP  - 3
DP  - 2022 Sep
TI  - Effects of inulin-type fructans with different degrees of polymerization on 
      inflammation, oxidative stress and endothelial dysfunction in women with 
      polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.
PG  - 319-330
LID - 10.1111/cen.14712 [doi]
AB  - OBJECTIVE: Polycystic ovary syndrome (PCOS) is associated with several 
      cardiovascular risk factors. Prebiotics were proposed to beneficially affect risk 
      factors associated with metabolic disorders. The aim of this study was to 
      investigate and compare the effects of inulin-type fructans (ITFs), as 
      well-studied prebiotics, with different degrees of polymerization, on markers of 
      inflammation, oxidative stress and endothelial dysfunction in PCOS patients. 
      DESIGN: A randomized, double-blind, placebo-controlled trial. PATIENTS: 
      Seventy-five PCOS women were randomly assigned to receive 10 g/day of either 
      high-performance inulin (HPI) or oligofructose-enriched inulin (OEI) or 
      placebo for 12 weeks. MEASUREMENTS: Biochemical indices and blood pressure 
      levelswere assessed before and after the intervention. RESULTS: In the 
      intent-to-treat analysis, high-sensitive C-reactive protein (hs-CRP) decreased in 
      HPI and OEI groups, over the 12 weeks, and the changes were significant in the 
      HPI group, compared to placebo (changes from baseline in the HPI group: -0.11 vs. 
      placebo group: 0.004 mg/L [conversion factor to SI units (nmol/L): 9/5238]; 
      p = .007). Serum levels of nitric oxide (NO) increased, and endothelin-1 and 
      total oxidant status decreased in HPI and OEI groups, at the end of the trial; 
      however, these changes were not significantly compared to placebo (p = .07, .36 
      and .22, respectively). No differences in systolic and diastolic blood pressure 
      were found. Per-protocol analysis (n = 68) yielded consistent results for all 
      endpoints, with the exception that the significant effect of ITFs on serum hs-CRP 
      levels in the unadjusted ITT analysis became nonsignificant in the per-protocol 
      analysis (p = .06). CONCLUSION: A 12-week supplementation with long-chain ITFs 
      had favourable effects on inflammatory status among PCOS patients.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Ziaei, Rahele
AU  - Ziaei R
AUID- ORCID: 0000-0002-9771-4936
AD  - Department of Community Nutrition, School of Nutrition and Food Science, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Shahshahan, Zahra
AU  - Shahshahan Z
AD  - Department of Obstetrics and Gynecology, School of Medicine, Isfahan University 
      of Medical Sciences, Isfahan, Iran.
FAU - Ghasemi-Tehrani, Hatav
AU  - Ghasemi-Tehrani H
AD  - Fertility Department, School of Medicine, Isfahan University of Medical Sciences, 
      Isfahan, Iran.
FAU - Heidari, Zahra
AU  - Heidari Z
AD  - Department of Biostatistics and Epidemiology, School of Health, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Ghiasvand, Reza
AU  - Ghiasvand R
AD  - Department of Community Nutrition, School of Nutrition and Food Science, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20220316
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Biomarkers)
RN  - 0 (Fructans)
RN  - 9005-80-5 (Inulin)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Biomarkers
MH  - C-Reactive Protein/metabolism
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - *Fructans/therapeutic use
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Inulin/therapeutic use
MH  - Oxidative Stress
MH  - *Polycystic Ovary Syndrome/drug therapy
MH  - Polymerization
OTO - NOTNLM
OT  - endothelium
OT  - inflammation
OT  - inulin
OT  - microbiota
OT  - polycystic ovary syndrome
OT  - prebiotics
EDAT- 2022/03/10 06:00
MHDA- 2022/08/04 06:00
CRDT- 2022/03/09 05:37
PHST- 2022/01/26 00:00 [revised]
PHST- 2021/11/06 00:00 [received]
PHST- 2022/02/16 00:00 [accepted]
PHST- 2022/03/10 06:00 [pubmed]
PHST- 2022/08/04 06:00 [medline]
PHST- 2022/03/09 05:37 [entrez]
AID - 10.1111/cen.14712 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2022 Sep;97(3):319-330. doi: 10.1111/cen.14712. Epub 2022 
      Mar 16.